Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Views - The company is positioned as a leader in the field of regenerative medicine, particularly in neurosurgery, with a diverse range of products driving significant revenue growth [19][25]. - The implementation of centralized procurement across multiple regions is expected to be a key factor in the company's performance release [19][26]. - The company's financial performance is projected to improve significantly, with expected revenues of 286 million yuan in 2024, 367 million yuan in 2025, and 482 million yuan in 2026, alongside a substantial increase in net profit [2][26]. Summary by Sections Company Overview - The company, established in 2008, focuses on high-performance implantable medical devices for neurosurgery, offering solutions for cranial repair, cerebrospinal fluid sealing, and hemostatic products [19][21]. - It has registered 10 Class III medical devices and holds over 250 effective patents, with products used in over 1,700 hospitals across China [19][21]. Financial Performance - The company reported a revenue of 195 million yuan in 2022, with a year-on-year growth of 27%, and an expected revenue of 231 million yuan in 2023, reflecting an 18.2% increase [2][26]. - In the first three quarters of 2024, the company achieved a revenue of 190.94 million yuan, a year-on-year increase of 30.98%, and a net profit of 52.80 million yuan, up 107.68% [26]. Product Development and Market Position - The company has successfully entered multiple provincial centralized procurement programs, enhancing its market penetration and sales volume [19][24]. - The artificial dura mater products have seen significant sales growth, with a reported revenue of 122.05 million yuan in the first half of 2024, a 42.38% increase year-on-year [24]. - The company is also expanding its product offerings in hemostatic materials, with the absorbable regenerated cellulose product expected to break the long-standing import monopoly in the market [24][25]. Management and Corporate Structure - The management team has extensive experience in the medical device industry, contributing to the company's stable governance and strategic direction [39][43]. - The company has implemented stock incentive plans to align employee interests with long-term business goals, enhancing motivation and performance [46][47].

Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Views - The company is positioned as a leader in the field of regenerative medicine, particularly in neurosurgery, with a diverse range of products driving significant revenue growth [19][25]. - The implementation of centralized procurement across multiple regions is expected to be a key factor in the company's performance release [19]. - The company has a stable management and ownership structure, with a stock incentive plan reflecting confidence in future business development [39][46]. Financial Forecast - The company is projected to achieve revenues of 286 million yuan in 2024, 367 million yuan in 2025, and 482 million yuan in 2026, with corresponding EPS of 1.09 yuan, 1.45 yuan, and 1.94 yuan respectively [2][9]. - The expected growth rates for revenue are 23.7% in 2024, 28.6% in 2025, and 31.3% in 2026 [2]. Business Overview - The company has a rich portfolio of neurosurgical products that meet various clinical needs, including artificial dura mater patches and hemostatic products [19][21]. - The company has successfully entered centralized procurement in several provinces, enhancing market penetration and sales volume [24][25]. - The company has established a strong international presence, with sales networks covering nearly 90 countries and regions, contributing to a 25.71% increase in overseas sales [25][26]. Product Development - The company has developed a comprehensive product matrix in neurosurgery, including artificial dura mater patches, craniofacial repair systems, and absorbable hemostatic products [19][21]. - The absorbable regenerated cellulose product is expected to break the long-standing import monopoly in the domestic market [24][25]. - The company has received multiple medical device registrations, enhancing its competitive edge in the market [19][20]. Management and Incentives - The management team possesses extensive experience in the medical device industry, contributing to the company's strategic direction and operational efficiency [39][43]. - The stock incentive plan aims to align employee interests with the company's long-term growth objectives, fostering motivation among key personnel [46][47].

共同投资的进展公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-006 广州迈普再生医学科技股份有限公司 关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资概述 为了进一步推进公司产业发展、基于战略规划考虑需要，公司作 为有限合伙人以自有资金 2,000 万元出资与德摩咨询（深圳）有限公 司、广州康臣药业有限公司、丁骏、张适安共同设立广东东纳协同产 业投资合伙企业（有限合伙）（以下简称"东纳协同"）。本次认缴 完成后公司持有东纳协同 48.7805%的合伙份额。东纳协同资金仅定 向用于认购/申购广东东纳私募基金管理有限公司所管理的广东东纳 医健创业投资合伙企业（有限合伙）（以下简称"东纳医疗基金"） 合伙份额。东纳协同作为有限合伙人以自有资金 4,100 万元与广东东 纳私募基金管理有限公司、河源市高新产业引导母基金投资中心（有 限合伙）共同设立东纳医疗基金。设立完成后，东纳协同持有东纳医 疗基金 79.5344%的合伙份额。 东纳医疗基金主要投向科技创新引领的医疗健康领域，其中 ...

与专业投资机构共同投资的公告 3、本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 4、公司将根据本次投资的后续进展情况，按照相关法律法规的规定和《公 司章程》的要求及时履行相应的信息披露义务，敬请广大投资者注意投资风险。 一、与专业投资机构共同投资概述 （一）本次投资基本情况 证券代码：301033 证券简称：迈普医学 公告编号：2025-005 广州迈普再生医学科技股份有限公司 关于与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、广州迈普再生医学科技股份有限公司（以下简称"公司"、"迈普医学"） 作为有限合伙人以自有资金 2,000 万元人民币（下同）参与投资广东东纳协同产 业投资合伙企业（有限合伙）（简称"东纳协同"），本次认缴完成后公司持有 东纳协同 48.7805%的合伙份额；东纳协同企业资金仅定向用于认购/申购广东东 纳私募基金管理有限公司所管理的广东东纳医健创业投资合伙企业（有限合伙） （简称"东纳医疗基金"）合伙份额。 2、近日，东纳协同作为有限合伙人以自有资金 ...

广州迈普再生医学科技股份有限公司 简式权益变动报告书 上市公司：广州迈普再生医学科技股份有限公司 股票代码：301033.SZ 信息披露义务人：唐莹 住所/通讯地址：广东省深圳市福田区 信息披露义务人之一致行动人：叶涛 住所/通讯地址：广东省深圳市福田区 股份权益变动性质：减少（持股比例下降至 5%以下） 签署日期：二零二五年二月十三日 1 上市地点：深圳证券交易所 股票简称：迈普医学 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披 露内容与格式准则第 15 号—权益变动报告书》等相关法律、法规和 规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其 履行亦不违反其章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》 的规定，本报告书已全面披露了信息披露义务人在迈普医学中拥有权 益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义 务人没有通过任何其他方式增加或减少其在迈普医学中拥有权益的 股份。 四、本次权益变动是根据本报告 ...

提示性公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-004 广州迈普再生医学科技股份有限公司 关于持股 5%以上股东权益变动的提示性公告 公司股东唐莹女士保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本次权益变动后，公司持股 5%以上的股东唐莹女士及其一致行 动人叶涛先生合计持有公司股份 3,325,977 股，占公司当前总股本 （即 66,519,431 股）的 5.0000%（占剔除公司回购专用账户股份数 量后总股本的 5.0266%）。 二、本次权益变动前后持股情况 特别提示： 1、本次权益变动属于持股 5%以上股东减持股份，不触发要约收 购； 2、本次权益变动后，公司持股 5%以上的股东唐莹女士及其一致 行动人叶涛先生合计持有公司股份 3,325,977 股，占总股本的 5.0000% （占剔除公司回购专用账户股份数量后总股本的 5.0266%）。 3、本次权益变动不会导致公司控制权的变更，不会对公司财务 状况、持续经营情况产生重大影响，同时也 ...

Group 1 - The core viewpoint of the news is that Maipu Medical (301033) has announced a significant increase in its expected net profit for 2024, projecting a net profit of between 70 million to 80 million yuan, which represents a year-on-year growth of 71.24% to 95.71% [1] - The stock price of Maipu Medical closed at 44.25 yuan, experiencing a decline of 1.12%, with a turnover rate of 0.64% and a trading volume of 15.8896 million yuan, while it has seen a slight increase of 0.14% over the past five days [1] - A statistical analysis of stocks with a profit forecast increase of over 50% indicates that 67.91% of these stocks experienced a price increase on the day of the announcement, with 22 companies hitting the daily limit up [1] Group 2 - Following the profit forecast announcement, 71.16% of the stocks saw an increase in price over the subsequent five days [2]

Revenue Forecast - The expected revenue for 2024 is between 275 million and 285 million RMB, representing a growth of 19.11% to 23.45% compared to 230.87 million RMB in the previous year[3]. Profit Forecast - The net profit attributable to shareholders is projected to be between 70 million and 80 million RMB, indicating a growth of 71.24% to 95.71% from 40.88 million RMB in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is expected to be between 60 million and 70 million RMB, reflecting an increase of 61.15% to 88.01% from 37.23 million RMB in the previous year[3]. - The company attributes the increase in net profit to enhanced marketing efforts and steady growth in main business revenue[6]. Financial Data and Reporting - The financial data in the earnings forecast has not been audited by an accounting firm[4]. - The specific financial data will be detailed in the company's 2024 annual report[7]. - The company emphasizes that the earnings forecast is based on preliminary calculations by the finance department[7]. Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[7].

培训情况报告 1 华泰联合证券有限责任公司关于 广州迈普再生医学科技股份有限公司持续督导期 2024年培训情况报告 深圳证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作 为广州迈普再生医学科技股份有限公司（以下简称"迈普医学"、"公司"）首次 公开发行股票并在创业板上市的保荐机构，根据《深圳证券交易所上市公司自律 监管指引第 13 号——保荐业务》《深圳证券交易所创业板股票上市规则》和《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 规和规则的相关规定以及迈普医学的实际情况，认真履行保荐机构应尽的职责， 对迈普医学的董事、监事、高级管理人员、中层以上管理人员及上市公司控股股 东和实际控制人等相关人员进行了有计划、多层次的后续培训，所培训的内容严 格按照中国证券监督管理委员会及深圳证券交易所有关持续督导的最新要求进 行。 2024 年 12 月 30 日，华泰联合证券相关人员按照《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》的要求完成了对迈普医学董事、监事、 高级管理人员、中层以上管理人员及上市公司控股股东和实际控制人等相关人员 ...

| 保荐人名称：华泰联合证券有限责任公司 被保荐公司简称：迈普医学 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：胡轶聪 联系电话：755-81902000 | | | | | 保荐代表人姓名：张冠峰 联系电话：755-81902000 | | | | | 现场检查人员姓名：胡轶聪 | | | | | 现场检查对应期间：2024 年度 | | | | | 现场检查时间：2024 年 月 日 12 30 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段： | | | | | （一）对上市公司董事、监事、高级管理人员及有关人员进行访谈； | | | | | （二）察看上市公司的主要生产、经营、管理场所； | | | | | （三）对有关文件、原始凭证及其他资料或者客观状况进行查阅、复制、记录、录音、录像、 | | | | | 照相； | | | | | （四）检查或者走访对上市公司损益影响重大的控股或参股公司； | | | | | 1.公司章程和公司治理制度是否完备、合规 | √ | ...